-
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Insulin glulisine in the management of diabetes
Review
(3218) Views (1281) Full article downloads
Author: Satoru Yamada
Published Date July 2009
Volume 2009:2 Pages 111 - 115
DOI: http://dx.doi.org/10.2147/DMSO.S3404
Satoru Yamada1,2
1Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Abstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.
Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20
Other articles by Dr Satoru Yamada
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Alogliptin: a new addition to the class of DPP-4 inhibitors
- Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
- The economic impact of obesity in the United States
- Adipose inflammation: cause or consequence of obesity-related insulin resistance
